BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33840396)

  • 1. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.
    Olivares JM; González-Pinto A; Páramo M;
    Eur Psychiatry; 2021 Apr; 64(1):e40. PubMed ID: 33840396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
    Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
    Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
    Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
    J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
    Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
    JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.
    Olivares JM; Fagiolini A
    Front Psychiatry; 2022; 13():877867. PubMed ID: 35573364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.
    Biagi E; Capuzzi E; Colmegna F; Mascarini A; Brambilla G; Ornaghi A; Santambrogio J; Clerici M
    Adv Ther; 2017 May; 34(5):1036-1048. PubMed ID: 28382557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
    Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
    J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
    Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
    CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment persistence with aripiprazole once monthly: a 4-year follow-up.
    Fagiolini A; Aguglia E; Ballerini A; Callista G; Carpiniello B; Clerici M; Corrivetti G; Cuomo A; De Fazio P; De Filippis S; De Giorgi S; Goracci A; La Barbera D; Mencacci C; Montagnani G; Pigato G; Vannucchi J; Vita A
    Ann Gen Psychiatry; 2022 Sep; 21(1):39. PubMed ID: 36175924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).
    Oluboka O; Clerzius G; Janetzky W; Schöttle D; Therrien F; Wiedemann K; Roy MA
    BMC Psychiatry; 2023 May; 23(1):383. PubMed ID: 37259053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.
    Peters-Strickland T; Zhao C; Perry PP; Eramo A; Salzman PM; McQuade RD; Johnson BR; Sanchez R
    CNS Spectr; 2016 Dec; 21(6):460-465. PubMed ID: 27531181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
    Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
    Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia.
    Such P; Bøg M; Kabra MS; Jørgensen KT; de Jong-Laird AC
    Prim Care Companion CNS Disord; 2021 Sep; 23(5):. PubMed ID: 34592798
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis.
    Kishi T; Sakuma K; Iwata N
    Pharmacopsychiatry; 2022 Nov; 55(6):291-296. PubMed ID: 35790191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
    J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.